Currently, it has been observed that the combined treatment of Bevacizumab and AAV9-LECT2-shRNA can significantly enhance the efficacy against liver fibrosis, however, a series of experimental studies are still needed for clinical application (63). This evidence concerns the gene LECT2 and Hepatic fibrosis.